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Abstract
Retinoic acid (RA) is the active metabolite of vitamin A and essential for many physiological processes, particularly
the induction of cell differentiation. In addition to regulating genomic transcriptional activity via RA receptors
(RARs) and retinoid X receptors (RXRs), non-genomic mechanisms of RA have been described, including the
regulation of ERK1/2 kinase phosphorylation, but are poorly characterised. In this study, we test the hypothesis that
genomic and non-genomic mechanisms of RA are regulated independently with respect to the involvement of ligand-
dependent RA receptors. A panel of 28 retinoids (compounds with vitamin A-like activity) showed a marked disparity in
genomic (gene expression) versus non-genomic (ERK1/2 phosphorylation) assays. These results demonstrate
that the capacity of a compound to activate gene transcription does not necessarily correlate with its ability
to regulate a non-genomic activity such as ERK 1/2 phosphorylation. Furthermore, a neurite outgrowth assay
indicated that retinoids that could only induce either genomic, or non-genomic activities, were not strong
promoters of neurite outgrowth, and that activities with respect to both transcriptional regulation and ERK1/2
phosphorylation produced maximum neurite outgrowth. These results suggest that the development of
effective retinoids for clinical use will depend on the selection of compounds which have maximal activity in
non-genomic as well as genomic assays.
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Background
Retinoids are a family of natural or synthetic com-
pounds that are analogues of vitamin A and its deriv-
atives [1]. They are essential for numerous cellular
activities including growth, proliferation and differen-
tiation of a variety of tissues, and are necessary for
central nervous system development, neuroplasticity
and neurite outgrowth [2]. Most actions of retinoids
are mediated by retinoic acid (RA), which is derived
from retinol in a two-step enzymatic process via a
retinaldehyde intermediate [3].
Retinoic acid (RA) has been described as a neurotrophic
factor that binds to nuclear receptors (RAR and RXR),
inducible ligand-activated transcription factors which
regulate multiple physiological mechanisms at a genomic
level [4, 5]. In addition to this ‘classical’ mechanism, RA
can exert non-genomic effects, mediated either by the
RARs or independent of them [6–8]. Several studies have
demonstrated that RA can activate kinases, such as ERK1/
2 [9–13], which may play a role in cytoskeletal rearrange-
ment and neurite outgrowth [14] in a number of cell
types. The RA signalling pathway also regulates neurite
outgrowth [15], a property demonstrated in several in
vitro models including neuroblastoma cell lines and pri-
mary neuron cultures [16–21]. Whether this is a result of
genomic or non-genomic effects, or a combination of such
mechanisms, is unknown.
A large number of synthetic retinoids have been gen-
erated as agonists of the RA nuclear receptors, but, in
contrast to the large number of published studies on
their regulation of gene expression, very few studies
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have characterised the non-genomic action of retinoids
in relation to their properties as RAR ligands. In this
study, we test the hypothesis that genomic and
non-genomic activities of retinoids are regulated inde-
pendently using a diverse range of commercially-available,
and novel RAR and RXR ligands for several of the differ-
ent classes of RA receptors (RARα/β/γ, RXRα/β/γ) or li-
gands for RBP4. The properties of these ligands were
compared with respect to activity in genomic (gene ex-
pression) assays and a non-genomic (ERK1/2 phosphoryl-
ation) assay, and their ability to induce neurite outgrowth.
Methods
Retinoid solutions
All-trans-RA (ATRA) (Sigma-Aldrich) was dissolved at a
concentration of 0.1M in dimethyl sulfoxide (DMSO)
under red light in a dark room, aliquoted into 0.6 ml
microtubes stored under nitrogen at − 70 °C, and
protected from light. Synthetic retinoids were dissolved in
DMSO as 0.01M stock solutions and stored at − 20 °C,
protected from light. A1120 and TTNPB were pur-
chased from Sigma-Aldrich, CD2665 was purchased
from Tocris; HX600 and DA124 were obtained from
Dr. Kagechika (Tokyo) while fenretinide was obtained
from Dr. Nimesh Mody (University of Aberdeen).
Other synthetic retinoids and non-retinoid homo-
logues were designed and synthesized as described
previously [22–28]. The molecular structures of the
RAR and RXR ligands used are shown in Fig. 1. The
majority of the compounds are effective activators of
RARs, except for A1120 (a RBP4 ligand), HX600 and
DA124 (RXR agonists), CD2665 (RAR β/γ antagonist)
and DC324, DC329 and DC303, which exhibit ex-
tended structures compared to their shorter analogues
(DC271, DC375 and EC23, respectively) that signifi-
cantly reduce their binding affinities for the RARs.
Fig. 1 Retinoids used in the study grouped into those that are RAR agonists, RXR agonists, RAR antagonists, poor RAR agonists and antagonists
for RBP4
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Cell culture
Sil-15 cells [29] were used in the X-Gal based RA reporter
assay, described below, to measure the transcriptional ac-
tivity of ATRA and other RAR and RXR ligands. This cell
line was derived [29] from F9 teratocarcinoma cells trans-
fected with a plasmid containing the LacZ gene under the
control of a promoter linked to the RARβ RARE [30, 31].
Sil-15 cells were cultured at 37 °C with 5% CO2 in T-75
flasks in Dulbecco’s Modified Eagle’s Medium (DMEM;
Thermo Fisher Scientific) containing 10% fetal calf serum
(FCS; Thermo Fisher Scientific), 0.8 mg/ml G418 disulfate
salt (Geneticin, Sigma-Aldrich) to maintain selection for
the LacZ plasmid; cells were passaged twice a week using
0.05% Trypsin-EDTA.
SH-SY5Y cells [32] were used in the neurite outgrowth,
ERK phosphorylation and RA genomic activity assays.
The cells were treated with varying concentration of reti-
noids for each assay depending on the results of previ-
ously performed pilot studies. These cells are a third
subclone of the SK-N-SH neuroblastoma cell line [33].
SH-SY5Y cells were grown in DMEM containing 10% FCS
at 37 °C with 5% CO2. The medium was changed three
times a week and the cells were passaged at 70% conflu-
ence using 0.05% trypsin-EDTA. The passage number
used for each experiment was no higher than 30.
X-gal based RA reporter assay
Sil-15 cells were used to detect and quantify the tran-
scriptional activity of retinoids added to the medium
by monitoring β-galactosidase activity produced by
the reporter cells. 96-well plates were coated with
0.1% gelatin for at least 2 h at 37 °C, washed twice
with PBS, wrapped with parafilm and stored at 4 °C
until use. Sil-15 cells were removed from stock cul-
ture flasks by trypsinization, counted and plated at
100,000 cells per well in the pre-coated 96-well plates.
After attachment overnight in DMEM containing 10%
FCS, the medium was replaced with fresh DMEM/
10% FCS and serial dilutions of retinoid ligands, pre-
pared in DMEM containing 10% FCS, were added at
concentrations from 10− 6 M to 10− 14 M. The plates
were incubated overnight at 37 °C / 5% CO2. All con-
centrations for the ATRA standard curve and the
other retinoid ligands were tested in triplicate. The
next day, the assay plates were washed twice with
PBS, fixed with 100 μl per well of 1% glutaraldehyde
and 1 mM MgCl2 in PBS for 15 min, washed twice
with PBS and β-galactosidase activity detected by add-
ing to each well 100 μl of freshly-prepared 0.2% X-Gal
in 1 mM MgCl2, 3.3 mM potassium ferricyanide and
3.3 mM potassium ferrocyanide in PBS. Plates were
incubated for 6 h at 37 °C in 5% CO2 and colour
change at 650 nm measured on an Emax Precision
Microplate Reader (Molecular Devices).
Gene expression analysis
Total RNA was extracted from SH-SY5Y cells treated with
10 nM retinoid ligands for 24 h using a Qiagen RNeasy mini
kit according to the manufacturer’s protocol. An extra
DNAse digestion step was carried out during RNA purifica-
tion to remove DNA contamination. cDNA was synthesized
from 250 ng total RNA using High qScript cDNA Synthesis
master mix. qPCR reactions using PerfeCTa SYBR Green
SuperMix were performed on a Roche LightCycler 480 and
analyzed using LightCycler 480 1.5 software. Primers
spanning exon-exon junctions were designed using
Primer-BLAST [34] for CYP26A1 (CACCGTACGGGTGA
TGGGCG, GCTGGCCAGTGGACCGACAC), RARβ
(GCTTAATCTGTGGAGACCGCCAGG, TGTGAGGCT
TGCTGGGTCGT), and GAPDH (TCTTTTGCGTCGCC
AGCCGA, AGTTAAAAGCAGCCCTGGTGACCA) genes.
Standard curves and blank controls were run for all
sets of primers tested. A housekeeping gene was
chosen for normalization by prescreening a range of
genes with experimental samples and choosing the
one showing least variability between samples, which
in this case was GAPDH.
ERK1/2 phosphorylation screening using the AlphaLISA®
SureFire® Ultra assay
The ability of ATRA and other RAR and RXR ligands to
phosphorylate ERK1/2 was determined in SH-SY5Y cells
using the AlphaLISA® SureFire® Ultra ERK1/2 kit (Perki-
nElmer). In this assay, SH-SY5Y cells (100,000 cells/well)
were plated in 96-well plates and serum-starved in
DMEM for 24 h. Retinoids were tested at concentrations
from 10− 5 M to 10− 11 M and at a final concentration of
0.1% DMSO in the medium. SH-SY5Y cells were assayed
in serum-free DMEM and stimulated for 30 min (deter-
mined from a time course experiment) at 37 °C. At the
end of the assay, the medium was removed, and cells
were lysed with 50 μl of freshly prepared 1X lysis buffer
supplied in the kit. The 96-well plate was agitated on an
orbital shaker SO1 (Stuart Scientific) at approximately
350 rpm for 10 min at room temperature. In the mean-
time, the activation buffer was diluted 25-fold in the re-
action buffers. Under green light in a dark room the
acceptor beads were diluted 50-fold in the freshly
prepared reaction mix while the donor beads were di-
luted 50-fold in dilution buffer to obtain two final re-
action mixtures. 10 μl of cell lysate was then
transferred to the wells of a 384-well white Proxi-
plates plate (PerkinElmer) and 5 μl of each prepared
acceptor and donor reaction mixtures was added
above the wells while still under green light in the
dark room. Plates were next wrapped with aluminium
foil and incubated at room temperature for at least 3
h and read with the Envision system (PerkinElmer
Life Sciences) using AlphaScreen® settings.
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Neurite outgrowth assay
16mm glass coverslips were acid treated in a mixture of
69% nitric acid and 37% hydrochloric acid in a 2:1 ratio
for 2 h. The coverslips were then washed extensively
with MilliQ deionised water until the pH of the water
reached 5.5–6. Until needed, the coverslips were stored
in a jar containing 70% ethanol. The coverslips were put
on a 70% ethanol-soaked tissue paper under the cell cul-
ture hood to dry. The coverslips were then placed in the
wells of 12-well plates. After that they were coated by
addition of 1 ml of poly-L-lysine (PLL) solution above
each coverslip in the well. The final concentration of
PLL solution used for coating was 0.002% and the incu-
bation time was 2 h at 37 °C. Two washes with sterile
PBS followed and afterwards the coverslips were air
dried under sterile conditions.
SY-SY5Y cells were removed from stock flasks by tryp-
sinization, counted and plated at 10,000 cells/well in
12-well plates containing acid-treated/PLL-coated cover-
slips. The plates were maintained at 37 °C in a humid at-
mosphere containing 5% CO2 for 24 h. Then, each
retinoid was added to the medium and tested at two dif-
ferent concentrations, 10 μM and 10 nM, with a final
DMSO concentration of 0.01% or 0.0001%, respectively.
The plates incubated for 5 days at 5% CO2 / 37 °C. All
retinoid concentrations were tested in triplicate.
After retinoid treatment, SH-SY5Y cells on coverslips
were washed twice in PBS, fixed in 4% paraformaldehyde
(PFA) for 20 min at room temperature, followed by two
washes with PBS. Coverslips were stored at 4 °C in PBS
until stained. For immunocytochemical staining of neur-
ites, cells on coverslips were washed three times in PBS,
and incubated in blocking solution (10% donkey serum
and 0.1% Triton X-100 in PBS) for 1 h at room
temperature. Cells were then labelled by incubation
overnight at 4 °C with β-III tubulin primary antibody
(Sigma-Aldrich) diluted 1:1000 in blocking buffer,
washed three times with PBS containing 0.1% Triton
X-100 solution (PBST) before incubation with
anti-mouse monoclonal secondary antibody (1:300 in
PBST; Jackson Immunoresearch) for 2 h at room
temperature. Finally, after three washes in PBST and a
final wash in PBS, the coverslips were mounted on slides
and stored at 4 °C.
ImageJ software with the NeuronJ plugin was used to
quantify neurite outgrowth on stained cells. For each ex-
periment, 10 different randomly selected images were
taken from each cover slip using a Nikon Eclipse E400
fluorescence microscope. Each image was converted into
an 8-bit image (necessary for the NeuronJ plugin) and
optimised with the brightness and contrast tool in GIMP
(GNU Image Manipulation Program). For each image,
individual traces were drawn for each clearly-identifiable
neurite using the tracing tool in the NeuronJ plugin.
Neurite length was measured in pixels and transformed
into the corresponding length in μm depending on the
magnification used. The average neurite length for each
image was calculated by dividing total neurite length by
the total number of neurites per image. Ten images per
cover slip were measured and the mean calculated for
the coverslip overall. Coverslips were in triplicate for
each retinoid and concentration.
Cell number assay
SH-SY5Y cells were plated on acid-treated/PLL-coated
coverslips, treated with retinoids as described previously
in the neurite outgrowth assay section, 4% PFA fixed
and stained with bisbenzimide dye (1 mg/ml). For each
experiment, 10 different randomly selected images were
taken from each cover slip using a Nikon Eclipse E400
fluorescence microscope. The number of cells were then
counted in each image manually, identifying each cell
from its bisbenzimide-labelled nucleus. Ten images per
cover slip were measured and the mean calculated for
the coverslip overall. Coverslips were in triplicate for
each retinoid and concentration.
Statistical analysis
All data are presented as mean ± SEM of three inde-
pendent experiments with biological triplicates. Statis-
tical analyses were performed in Microsoft Office Excel
2017, GraphPad Prism 7.0c version (Prism, GraphPad
Software, San Diego, CA) and R version 3.3.1 (R Core
Team, 2016) [35]. Gene expression and Neurite
Outgrowth data were analysed by Student’s t-test or
one-way ANOVA with Newman-Keuls multiple
comparison test as appropriate; P value < 0.05 was
considered statistically significant. * P < 0.05, ** P < 0.01,
*** P < 0.001, **** P < 0.0001. Data for X-Gal and ERK1/2
phosphorylation were analysed using sigmoidal
dose-response analysis of log (agonist) versus response
curve (stimulation). Non-parametric (Spearman) and para-
metric (Pearson) correlation analyses were used to compare
cell responses, and asymptotic Wilcoxon-Mann-Whitney
tests for non-parametric two-way comparisons of neurite
length and cell number, where appropriate. Non-parametric
correlation analyses were used for comparisons involving
transcriptional data so that outliers could be included
without bias. The results of analyses were presented
as Emax and EC50 with 95% confidence interval limits
(95% CI).
Results
Genomic activity of retinoids
To quantify genomic (transcriptional regulation) activity,
the Sil-15 RA reporter cell line, in which X-gal expres-
sion is driven by a RARβ RARE, was used to assay reti-
noids at concentrations ranging from 10− 6 M to 10− 14
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M. In these assays (Fig. 2), the EC50 value represents the
half-maximal effective concentration (potency) and is re-
lated to the affinity for the receptor; the maximum
stimulation, defined by the Emax value, is a measure of
the compound efficacy. Of the 28 retinoids tested, nine
(HX600, DA124, EC19, CD2665, DC375, DC324,
DC329, DC476 and DC479) did not have any genomic
activity compared to ATRA. However, 19 compounds
were effective in inducing a genomic response. Three
retinoids, EC23, TTNPB and GZ25, had significantly
lower EC50 than ATRA and TTNN, DC128, AH61, and
DC271 had similar potencies to ATRA; the other reti-
noids had significantly higher EC50 values than ATRA
(Fig. 2).
In addition, the compounds varied in their efficacy
(Emax). Not all compounds with higher potency com-
pared to ATRA also exhibited higher efficacy, and vice
versa. For example DC271 and TTNPB had lower Emax
values, even though their EC50 values were lower or the
same as ATRA. EC23Al (the aldehyde of EC23) showed
a significantly higher Emax while the EC50 was greater
compared to ATRA. Moreover, GZ25 exhibited a signifi-
cantly higher Emax compared to ATRA, and also showed
greater potency than ATRA. The potency and efficacy of
each ligand along with the 95% confidence intervals (CI)
in inducing a genomic activity are summarised in Add-
itional file 1 :Table S1.
To confirm the activity of these retinoids on endogen-
ous transcriptional regulation in the SH-SY5Y cell line
used for neurite outgrowth and non-genomic activity as-
says, two genes with well-defined RAREs in their pro-
moters were investigated: RARβ and CYP26A1 [30, 36–
38]. In these assays, the fold change in RARβ and
CYP26A1 gene expression in SH-SY5Y cells treated with
10 nM concentrations of RAR and RXR ligands were
compared to a DMSO control (Fig. 3). EC23, AH61,
EC23Al, TTNN and JBGG179 all had greater potency
than ATRA at inducing CYP26A1 and RARβ. DC444 in-
duced CYP26A1 and RARβ gene expression to almost
the same extent as ATRA. Fenretinide, DC440 and
DC271 induced CYP26A1 and RARβ but were weaker
than ATRA, while DC360 and DC476 only induced
RARβ. The other RAR and RXR ligands did not activate
CYP26A1 or RARβ. These gene expression results were
generally comparable to the results obtained with the
X-Gal RA based reporter assay; a key result is that GZ25
and EC23 were stronger in their genomic activity com-
pared to ATRA at low concentrations in both assays.
Non-genomic activity (ERK1/2 phosphorylation) induced
by retinoids in SH-SY5Y cells
SH-SY5Y cells have been reported to respond in a
non-genomic manner to the nuclear receptor ligand,
ATRA, with an increase in ERK1/2 activity [39–41].
Therefore, changes in ERK1/2 activity, detected as
ERK1/2 phosphorylation, in response to retinoids were
compared to ATRA as a positive control (Fig. 4). In
these experiments we could confirm that ATRA was a
strong activator of ERK1/2 kinase phosphorylation [40,
42, 43]. Of the other retinoids, nine (A1120, CD2665,
HX600, GZ25, DC329, DC440, DC472, DC476 and
TTNN) induced ERK1/2 phosphorylation with an EC50
that was significantly lower than ATRA. Five ligands,
AH61, EC23, DA124, DC128 and DC324, had EC50
values for ERK1/2 phosphorylation similar to ATRA.
The remaining retinoids were less potent compared
to ATRA (Fig. 4).
With respect to efficacy, 13 of the RAR and RXR li-
gands (EC23, EC23Al, HX600, GZ25, DC122, DC271,
DC303, DC360, DC440, DC472, DC476, DC479 and
DC547) had Emax values significantly higher than ATRA.
Six retinoids, AH61, A1120, CD2665, DA124, DC324
and TTNN, had similar efficacies to ATRA. The efficacy
of the rest of the retinoids was significantly lower than
ATRA. The potency and efficacy of each ligand along
with the 95% confidence intervals (CI) in inducing
ERK1/2 phosphorylation are summarised in Additional
file 1 :Table 1.
Neurite outgrowth and number of SH-SY5Y cells
increased by retinoids
The SH-SY5Y cell line can be induced by ATRA towards
a neuronal phenotype and is used as a model to study
neuronal differentiation and neurite outgrowth [44]. In
addition, ATRA stimulates an increase in cell number in
SH-SY5Y cell cultures [9]. Each retinoid was tested at
two different concentrations, 10 μM, as an assay of rela-
tive efficacy, and 10 nM as a measure of relative potency
(Figs. 5 and 6).
As in previous studies, ATRA at 10 μM induced neur-
ite outgrowth of SH-SY5Y cells [45]. EC23, AH61 and
GZ25 induced neurite outgrowth of SH-SY5Y cells at
the two tested concentrations, and with substantially
higher relative potency compared to ATRA. Fenretinide
induced death of almost all the SH-SY5Y cells at 10 μM
concentration; SH-SY5Y cells have a particular sensitivity
to fenretinide which induces apoptosis in a concentra-
tion dependent manner [46–48]. Conversely, fenretinide
significantly induced neurite outgrowth at 10 nM con-
centration. A1120 and DC271, DC128 and TTNN also
induced neurite outgrowth of the SH-SY5Y cells at the
two tested concentrations. TTNPB, DC360, DC303,
DC122, DC440, EC23Al and DC547 induced neurite
outgrowth at 10 μM concentration only. HX600, DA124,
DC318, CD2665, DC375, DC324, DC329, DC476,
JBGG179, DC479 and EC19 did not have visible effects
on neurite outgrowth in the SH-SY5Y cells at either con-
centration. The fold increase in neurite outgrowth
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Fig. 2 The concentration-response graph for log (agonist) vs. sigmoidal dose-response in evaluating ATRA versus retinoids in inducing genomic
response of Sil-15 reporter cells. Absorbance values of different retinoid doses were measured at 650 nm and analysed using sigmoidal dose-
response curves. Shown are average absorbance of three independent experiments. Error bars indicate standard error of the mean (SEM).
Statistically significant differences are indicated by non-overlapping 95% CI
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induced by each ligand is summarised in Additional file
1: Table S1. The number of neurites per cell was
also determined but this did not change significantly
between retinoid treatment (data not shown).
Cell number was measured in SH-SY5Y cultures
after each retinoid treatment (Fig. 6). ATRA, EC23,
AH61, GZ25, TTNPB, EC19, A1120, DC271, DC360,
DC128, DC440, EC23AL and TTNN increased
SH-SY5Y cell number significantly at the two tested
concentrations. EC23, AH61 and GZ25 increased the
number of cells at 10 nM concentration with signifi-
cantly higher relative potency compared to ATRA.
DC375 and DC472 increased SH-SY5Y cells signifi-
cantly at 10 nM concentration only. The rest did not
have significant effects on the number of SH-SY5Y
cells at either concentration.
Overall, there was a significant positive correlation
between the increase in neurite length and cell num-
ber induced by the retinoids (correlation coefficient,
Pearson, 0.77; P < 0.00001), while there was no signifi-
cant correlation between ERK1/2 activity (Emax) and
transcriptional activation activity (Emax) of the reti-
noids tested (n = 28, Spearman r = 0.2, P = 0.29). This
suggests that the genomic and non-genomic proper-
ties of the retinoids tested are independent.
Relationship of ERK1/2 kinase activity to neurite
outgrowth and cell number
For retinoids that increased neurite length there was no
significant correlation between ERK activity (Efficacy,
Emax) and neurite length (correlation coefficient,
Pearson, 0.28; P = 0.3); conversely, there was a significant
positive correlation between neurite length and tran-
scriptional activity (Emax, correlation coefficient, Spear-
man, 0.6, P = 0.014). This suggests a proportional
relationship between genomic properties of retinoids
and increasing neurite length but a lack of such propor-
tional relationship with respect to ERK1/2 activity as a
non-genomic effect. For cell number, using all data (in-
cluding retinoids that did not increase neurite length),
there was no significant correlation with ERK activity
(correlation coefficient, Pearson, 0.315; P = 0.1), but, as
with neurite length, there was a significant correlation
between cell number and transcriptional activity (correl-
ation coefficient, Spearman, 0.745, P < 0.0001), again
suggesting that the genomic effects of retinoids are im-
portant determinants of cell responses. Plots showing
correlation analysis are illustrated in Additional file 2:
Figure S1.
For retinoids that increased neurite length, signifi-
cantly shorter neurites were induced by retinoids (n
Fig. 3 Analysis of the effects of 10 nM retinoid treatment on SH-SY5Y cells according to CYP26A1 and RARβ RNA levels by RT-qPCR. SH-SY5Y cells
were treated with 10 nM retinoids for 24 h. RNA was isolated and a) CYP26A1 or b) RARβ RNA analysed by qPCR. CYP26A1 and RARβ RNA levels
were standardised with respect to the GAPDH RNA control and compared to levels in control untreated cells (CT) which were set at 1. Shown are
mean values of three independent experiments analysed in triplicate. Error bars are SEM (* p < 0.05; ** p < 0.01, one-way ANOVA with Newman-
Keuls multiple comparison test). Several of the tested RAR and RXR ligands increased the expression levels of CYP26A1 and RARβ genes
significantly above control indicative of transcriptional activity, however, few were more potent than ATRA
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Fig. 4 Sigmoidal concentration-response graphs for induction of ERK1/2 phosphorylation in SH-SY5Y cells. Absorbance values of different retinoid
doses were measured at 570 nm. The average absorbance in three independent experiments are shown. Error bars indicate SEM. There was a
statistical difference in the potency (EC50) between ATRA and (A1120, CD2665, HX600, GZ25, DC329, DC440, DC472, DC476, TTNN), and the
efficacy (Emax) between ATRA and (EC23, EC23Al, HX600, GZ25, DC122, DC271, DC303, DC360, DC440, DC472, DC476, DC479) calculated by the
non-overlapping 95% CI
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= 4) that had no detectable ERK1/2 activity com-
pared to retinoids (n = 16) that had activity in both
the ERK1/2 and transcriptional assays (Asymptotic
Wilcoxon-Mann-Whitney Test; P = 0.012). However,
this was not the case for increases in cell number
(Asymptotic Wilcoxon-Mann-Whitney Test; P =
0.11).
To confirm that non-genomic activity is necessary for
retinoids to promote neurite outgrowth, kinase activity
was blocked using the MEK1/2 inhibitor U0126 (Tocris)
at a concentration of 10 μM. The MEK1/2 inhibitor
U0126 produced a significant decrease in the neurite
outgrowth induced by ATRA and EC23 (Fig. 7); neurite
outgrowth was decreased 2.7-fold and 3.3-fold in ATRA-
Fig. 5 Neurite outgrowth of SH-SY5Y cells treated with retinoids. SH-SY5Y cells were treated with the retinoids or DMSO CT treatment for 5 days,
and then neuronal differentiation was evaluated by immunofluorescence and morphometric analysis, using βIII-tubulin antibody. The average
length of neurites extending from SH-SY5Y cells after a) 10 μM and b) 10 nM compound treatment was measured and compared with the
control and ATRA. Shown are mean values of three independent experiments. The average neurite length was calculated by dividing the total
neurite length by the total number of neurites in each micrograph. Error bars indicate SEM (* p < 0.05; *** p < 0.001; **** p < 0.0001 one-way
ANOVA with Newman-Keuls multiple comparison test). c) Representative micrographs of SH-SY5Y cells stained with βIII-tubulin antibody after 10
nM retinoid treatment for 5 days (scale bar = 18 μm)
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and EC23-treated cells, respectively, after adding the
MEK1/2 inhibitor. MEK1/2 lies upstream of the ERK
signaling pathway and these results imply that the
MEK1/2 – ERK1/2 kinase signal transduction pathway is
important in facilitating ATRA-induced neurite out-
growth. In addition, MEK1/2 inhibitor did not have an
effect on SH-SY5Y cell number compared to control (re-
sults not shown).
Discussion
Since the discovery of RA receptors as members of the
nuclear receptor family of transcriptional regulators [49],
the emphasis on retinoid function has been on their
control of gene expression and a large number of syn-
thetic retinoids have been generated [50] and investi-
gated for their genomic activating properties. However,
nuclear receptors can also have important non-genomic
Fig. 6 Increase in number of SH-SY5Y cells treated with retinoids. SH-SY5Y cells were treated with the retinoids or DMSO CT treatment for 5 days,
and then number of cells evaluated by staining with bisbenzimide dye and counting the cells. The average number of SH-SY5Y cells after a)
10 μM and b) 10 nM compound treatment was measured and compared with the control and ATRA. Shown are mean values of three
independent experiments. Error bars indicate SEM (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 one-way ANOVA with Newman-Keuls
multiple comparison test). c) Representative micrographs of SH-SY5Y cells stained with bisbenzimide dye after 10 nM retinoid treatment for 5 days
(scale bar = 18 μm)
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actions [7, 51]. Such non-genomic roles have also been
proposed for the RA receptors, although the topic has
remained relatively unexplored and is complex, with RA
controlling multiple non-genomic pathways including
regulation of kinases [52] and protein translation [53].
In this study, the 28 retinoids investigated varied in
their genomic activity according to the differences in
molecular structure and their relative affinities for the
different receptors. For example, EC23 and GZ25, com-
pounds that exhibit strong binding affinities for the
RARs, were the most potent, followed by TTNPB,
DC128, AH61, and DC271. Conversely, compounds with
low affinity for the RARs, such as the RXR ligands
DA124 and HX600 or the extended DC324 and DC329,
did not induce a genomic response. In these respects,
the results from the X-gal activity assays and the gen-
omic activity of the compounds as inducers of RARβ
and CYP26A1 expression in SH-SY5Y cells were com-
parable, and the most potent ligands in the X-Gal re-
porter assay were also strong inducers of RARβ and
Fig. 7 MEK1/2 kinase involvement in neurite outgrowth. SH-SY5Y cells were treated with ATRA and EC23 with/without U0126 MEK1/2 inhibitor
for 5 days, and then neuronal differentiation was evaluated by immunofluorescence and morphometric analysis using βIII tubulin antibody.
Neurite outgrowth was significantly reduced after applying U0126. Typical micrographs are shown in a) DMSO CT, b) MEK1/2 inhibitor, c) 10 μM
of ATRA and MEK1/2 inhibitor, d) 10 μM ATRA, e) 10 μM of EC23 and MEK1/2 inhibitor, f) SH-SY5Y cells with 10 μM EC23 (scale bar = 18 μm). Error
bars indicate SEM of three biological replicates (** p < 0.01; *** p < 0.001; **** p < 0.0001 two-way ANOVA with Sidak’s multiple comparison test)
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CYP26A1. Nevertheless, in these experiments the
CYP26A1 gene was induced to a much higher extent
than the RARβ gene. This could be because the
CYP26A1 gene has two RAREs that work synergistically
[54]. Furthermore, the basal levels of CYP26A1 expres-
sion were very low; hence, when the cells are treated
with retinoids the fold increase in CYP26A1 will be very
high compared to the fold change in RARβ.
In the ERK1/2 phosphorylation assays, several reti-
noids lacked the ability to phosphorylate ERK1/2,
whereas others were more effective than ATRA. Use of
this assay helped us to identify novel properties for many
of these compounds and little connection was found be-
tween induction of genomic versus non-genomic signal-
ling, suggesting that quite different pathways mediate
these two activities. TTNPB, DC318, DC444 and
JBGG179, which were potent activators of gene tran-
scription, did not show any detectable capacity to induce
ERK1/2 phosphorylation compared to ATRA. In con-
trast, HX600, DA124, EC19, CD2665, DC375, DC324,
DC329, DC476 and DC479, which did not have genomic
activity, induced ERK1/2 phosphorylation. In addition,
we show that the RAR β/γ antagonist CD2665 could act
as an agonist for ERK 1/2 phosphorylation. Moreover,
two ligands for the RXR class of RA receptors (HX600
and DA124) induced ERK 1/2 phosphorylation, revealing
a novel property of this class of ligand.
While the activities of the retinoids in the separate
genomic and non-genomic assays suggest that these
functions are determined by different structural proper-
ties, a key result is that retinoids with both genomic and
non-genomic inducing activities had the highest
enhancing effects on neurite outgrowth, while com-
pounds with only one activity tended to induce neurite
outgrowth with lower efficiency (Fig. 8a). For example,
EC23, AH61 and GZ25, which had the greatest enhancing
effect on neurite length, were also strong inducers of gene
transcription and ERK1/2 phosphorylation. Retinoids with
only one activity did not induce neurite formation at low
(10 nM) treatment concentrations.
When testing the correlation between retinoid tran-
scriptional potency or ERK1/2 activation potency with
neurite outgrowth or cell number, transcriptional activa-
tion activity correlated with neurite outgrowth and cell
number while ERK1/2 potency correlated with neither.
However, retinoids without detectable ERK1/2 induced
significantly shorter neurites compared to retinoids with
ERK1/2 inducing activity. Further, inhibitors of ERK1/2
activity blocked retinoid induced neurite outgrowth.
These data indicate that ERK1/2 is required for
retinoid-induced neurite outgrowth and influences
length but it is potency of transcriptional activity of the
retinoids that is directly proportional to neurite out-
growth. The induction of ERK1/2 activity by retinoids
did not appear to influence cell number, although one
mechanism by which retinoids increase number of
SH-SY5Y cells is through increased cell survival in an
ERK1/2 dependent mechanism [9]. Because the time
scales of the ERK1/2 and transcriptional assays differ by
an order of magnitude, and the neurite and cell-number
responses are measured after 5 days, it would be
premature to discount a continuing role of ERK1/2 in
control of cell number. To address this issue adequately,
time-course analyses guided by computational
Fig. 8 The relationship between the genomic and non-genomic activities and neurite outgrowth and cell number in SH-SY5Y cells. Retinoids
with both genomic and non-genomic inducing activities had the highest enhancing effects on a) neurite outgrowth and b) cell number
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modelling, coupled with bioinformatic approaches to
data collection and analysis, will be required.
One mechanism by which ATRA promotes neurite
outgrowth is through regulation of the transcription of
neurotrophin genes, such as nerve growth factor (NGF)
and brain derived neurotrophic factor (BDNF), which
are important regulators of survival and neurite out-
growth [55, 56], and increasing the expression of TrkB,
the receptor for BDNF in SH-SY5Y cells [17, 45]. Fur-
thermore, a number of genes that are downstream tar-
gets of ATRA genomic activity have been shown to
function as neurite regulating factors [57–61].
A second mechanism of ATRA induced neurite out-
growth is through kinase activation. A number of kinase
pathways have been associated with ATRA’s ability to in-
duce neurite outgrowth in neuroblastoma cells such as
ERK1/2 [62, 63], c-Jun N-terminal kinase (JNK) [64–66]
and PI3K [67]. The action in this study of the MEK1/2
inhibitor to reduce neurite outgrowth in EC23 and
ATRA treated cells supports the importance of the
MEK1/2-ERK1/2 pathway. These different kinase path-
ways have been shown to play an important role in cyto-
skeletal reorganization and the modulation of neurite
outgrowth [56, 68]. For example, phosphorylated ERK1/
2 regulates microtubule dynamics by phosphorylating
different microtubule associated proteins and it also en-
ters the nucleus and activates various transcription fac-
tors such as cAMP response element binding (CREB)
protein required for axonal growth [56]. Yu and col-
leagues [66] reported that the JNK pathway plays a role
in ATRA induced neurite outgrowth in SH-SY5Y cells as
neurite outgrowth in the cells was repressed after inhi-
biting JNK. Lee and Kim [64] showed that the ERK path-
way is essential for ATRA induced neurite outgrowth in
SK-N-BE(2)C neuroblastoma cells. Additionally, it was
reported that ATRA induced PI3K leads to the activation
of the Rac1 G-protein, which is important for neurito-
genesis and PI3K inhibition impaired ATRA induced
neurite outgrowth in SH-SY5Y cells [67].
The routes by which the retinoids described in this
study regulate non-genomic actions are very diverse, fre-
quently rapid and involve a receptor in the cytoplasm.
RARα is particularly prominent in such a role. In the
cytoplasm RARα acts as an mRNA binding protein to
regulate protein translation [53]. It is also present in
lipid rafts of the plasma membrane (in MCF7 cells), and
retinoic acid rapidly activated P38MAPK in MCF7, HeLa
cells, F9 mouse embryocarcinoma cells and mouse em-
bryonic fibroblasts with Gq protein α subunit acting as
an intermediate [69]. Alternatively, in SH-SY5Y cells
RARα, again at the plasma membrane, interacts with
PI3K to activate ERK1/2 [70] while in the cytoplasm of
neuronal LA-N-5 cells RARγ interacts with c-src kinase
to control neurite outgrowth [71]. The complexity of
pathways does not end there. The cytoplasmic receptor
for RA and related compounds mediating non-genomic
actions do not necessarily need to be an RAR. For in-
stance, a cytoplasmic function for RA in CJ7 embryonic
stem cells and COS1 (kidney) cells to induce rapid
ERK1/2 activation uses cellular retinoic acid binding
protein 1 (CRABPI) [72]. RA can itself directly bind to
kinases such as Protein kinase C alpha [73] while in the
neuronal cell line PC12 CaMKII has a vital role to play
in RA activation of ERK1/2 [74]. Thus, some of the ac-
tions of the compounds described in the study to acti-
vate ERK1/2 may not be through the RARs themselves.
Conclusions
This study showed that the tested retinoids varied in
their ability to activate gene transcription and the
non-genomic pathways via ERK1/2 activation, and that
some compounds exhibit activity corresponding to the
modulation of only a single pathway. Furthermore, li-
gands that activate both genomic and non-genomic
pathways had the highest activity in assays for neuronal
cell number and neurite outgrowth. Thus, such
dual-potency retinoids can be developed in order to con-
siderably enhance their activity as promoters of neurite
outgrowth and neuronal cell number. Alternatively, reti-
noids with pathway specificity can be developed to po-
tentially reduce side-effects. These results have
important implication for the further development of
these drugs for neurodegenerative disorders.
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